NeuroDerm
NeuroDerm is an Israel-based clinical-stage pharmaceutical company and wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation, developing ND0612 (Onerji), a continuous subcutaneous infusion of liquid levodopa/carbidopa for Parkinson's disease patients with motor fluctuations.
- Company typePrivate
- Founded2003
- HeadquartersRehovot, Israel
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeuroDerm does
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company developing next-generation drug-device combination therapies for central nervous system disorders. Founded in 2003 and headquartered in Rehovot, NeuroDerm is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), part of the Mitsubishi Chemical Group. The company was previously publicly traded on NASDAQ under the ticker NDRM before its acquisition by MTPC, and now operates with 101-250 employees focused on R&D while MTPC manages global regulatory submissions and commercial strategy.
NeuroDerm's flagship product is ND0612, marketed as Onerji in the European Union, a continuous subcutaneous infusion of liquid levodopa/carbidopa designed to treat motor fluctuations in patients with advanced Parkinson's disease. The drug-device combination integrates a proprietary liquid pharmaceutical formulation of gold-standard levodopa/carbidopa with state-of-the-art portable infusion pump systems (the YURWAY Delivery System or Crono Twin ND pump), intended for 24-hour continuous self-administration at home. Phase 3 BouNDless trial data demonstrated a statistically significant 1.72-hour increase in ON time without troublesome dyskinesia (p<0.0001) and a 1.4-hour reduction in daily OFF time compared to oral immediate-release levodopa/carbidopa, with only 6% discontinuation during the double-blind period. Results were published in The Lancet Neurology in March 2024.
NeuroDerm's revenue model is pharmaceutical product sales of a prescription-only drug-device combination therapy, distributed through neurologists, movement disorder specialists, and specialty hospitals following regulatory approval. The European Commission granted marketing authorization for Onerji on April 27, 2026, marking the company's first commercial revenue opportunity, while the U.S. FDA accepted the NDA resubmission in May 2025 with a PDUFA target action date in Q3 FY2025. Historical funding prior to MTPC ownership totaled approximately $170 million across rounds in 2007, 2014, 2015, and 2016, with the $75 million 2016 round led by an undisclosed investor. As a wholly-owned subsidiary, NeuroDerm's R&D operations are funded internally by MTPC rather than through external capital markets.
NeuroDerm firmographics
Firmographics- Name
- NeuroDerm
- Legal name
- NeuroDerm Ltd.
- Website
- https://neuroderm.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- NeuroDerm is an Israel-based clinical-stage pharmaceutical company and wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation, developing ND0612 (Onerji), a continuous subcutaneous infusion of liquid levodopa/carbidopa for Parkinson's disease patients with motor fluctuations.
- Ownership category
- akta.pro rank
NeuroDerm industry classification
Industry- Product category
- Pharmaceutical drug-device combination therapies
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where NeuroDerm is headquartered
LocationHeadquarters
- HQ city
- Rehovot
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
NeuroDerm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: NeuroDerm generates revenue through the sale of pharmaceutical products. Their flagship product ND0612 (marketed as Onerji in EU) is a drug-device combination therapy for Parkinson's disease. The company received European Commission marketing authorization on April 27, 2026, marking the first commercial revenue opportunity. In the US, FDA has accepted the NDA resubmission with PDUFA target action date.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
NeuroDerm product offering
Product offeringCore offering
NeuroDerm develops next-generation drug-device combination therapies for central nervous system disorders. Its flagship product ND0612 (marketed as Onerji® in the EU) is a 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa for treating motor fluctuations in people with advanced Parkinson's disease, integrating a proprietary liquid pharmaceutical formulation with a portable pump delivery system (YURWAY® Delivery System or Crono Twin ND pump) and digital health solutions.
Product overview
NeuroDerm develops next-generation drug-device combination solutions for central nervous system disorders. The company's flagship product is ND0612 (marketed as Onerji® in the EU), which integrates a proprietary pharmaceutical formulation of levodopa/carbidopa using state-of-the-art delivery systems and digital solutions for continuous subcutaneous treatment of Parkinson's disease patients experiencing motor fluctuations. The product is administered via portable infusion pump systems (YURWAY® Delivery System or Crono Twin ND pump) and is designed to reduce disease burden and improve quality of life by providing steady drug delivery compared to oral medications.
Differentiator
Problem solved
Functional benefit
Brands
- Onerji®: EU brand name for ND0612 - a continuous subcutaneous infusion of liquid levodopa/carbidopa for the treatment of motor fluctuations in advanced Parkinson's disease.
Products and services
- ND0612 (Onerji® in the EU) A drug-device combination therapy providing 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for treatment of motor fluctuations in people with advanced Parkinson's disease. ND0612/Onerji® integrates a proprietary liquid levodopa/carbidopa formulation with a portable pump delivery system (YURWAY® Delivery System or Crono Twin ND) and digital health solutions, designed for self-administration at home and distributed through specialist prescribers, hospitals, and specialty pharmacies following regulatory approval.
Quantifiable outcome
- Increased ON time without troublesome dyskinesia by 1.72 hours compared to oral immediate-release levodopa/carbidopa (p<0.0001)
- +5 more outcomes
Companies that use NeuroDerm
Customer profileSegments1 record
Ideal customer profiles1 record
NeuroDerm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
NeuroDerm partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Mitsubishi Tanabe Pharma CorporationcoreNeuroDerm is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), part of the Mitsubishi Chemical Group. MTPC is the parent company that acquired NeuroDerm and funds its R&D operations. MTPC handles regulatory submissions (FDA, EMA) and commercialization. NeuroDerm develops the product in Israel while MTPC manages global regulatory and commercial strategy.
Scale indicators6 records
Recent moves5 records
Expansion highlights4 records
NeuroDerm competitors and assessment
Company assessmentDirect peers
- AbbVie: AbbVie markets Duopa/Duodopa (levodopa/carbidopa intestinal gel), the incumbent continuous-delivery therapy for advanced Parkinson's motor fluctuations, making it the most direct comparator for NeuroDerm's ND0612 subcutaneous infusion in both mechanism and indication.
- Lundbeck: Lundbeck is a specialty CNS pharmaceutical company with a deep Parkinson's portfolio (e.g., Onapgo apomorphine subcutaneous infusion) and competes head-to-head with ND0612 for advanced-PD prescribers.
- Supernus Pharmaceuticals: Supernus markets Gocovri (amantadine extended-release) for Parkinson's dyskinesia and acquired Adamas, giving it a CNS-focused Parkinson's franchise that competes with ND0612 in advanced-PD motor complication management.
- Britannia Pharmaceuticals: Britannia markets APO-go (apomorphine) including continuous subcutaneous infusion for Parkinson's motor fluctuations, making it a direct competitor to NeuroDerm's ND0612 in the continuous-subcutaneous advanced-PD niche.
- US WorldMeds: US WorldMeds markets Xadago (safinamide) and other Parkinson's therapies in the US, operating in the same advanced-PD symptomatic market as ND0612 and competing for movement-disorder specialist prescribing.
Emerging players
- Intec Pharma: Intec Pharma developed the Accordion Pill, an oral gastric-retention levodopa/carbidopa delivery platform for Parkinson's motor fluctuations—a partial competitor to ND0612 in improving LD pharmacokinetics in advanced PD.
- Sage Therapeutics: Sage is a CNS specialty biopharma focused on brain-health disorders; its positioning as a small-molecule CNS innovator makes it a comparable peer in CNS drug-development capability, though it does not directly compete in Parkinson's motor fluctuations.
- Herantis Pharma: Herantis Pharma is a small European CNS-focused biotech developing Parkinson's therapies (e.g., HER-096), making it a comparable EMERGING_PLAYER in drug-development-stage Parkinson's innovation.
Broad incumbents
- Cerevel Therapeutics: Cerevel (acquired by AbbVie) is a CNS-focused biopharma spanning neuroscience indications; its neuroscience drug-development approach is comparable to NeuroDerm's CNS specialty pharma positioning, even though Parkinson's was not its primary focus.
Regional players
- Kyowa Kirin: Kyowa Kirin is a Japan-headquartered specialty pharma with CNS and Parkinson's assets (e.g., NOURIAZ in Asia), making it a regional peer to MTPC-owned NeuroDerm in the Japanese/Asian advanced-PD market.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
NeuroDerm social profiles
Digital presenceNeuroDerm financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroDerm leadership team
Management profileNumber of profiles
Profiles9 records
NeuroDerm funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroDerm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroDerm
What does NeuroDerm do?
NeuroDerm develops next-generation drug-device combination therapies for central nervous system disorders. Its flagship product ND0612 (marketed as Onerji® in the EU) is a 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa for treating motor fluctuations in people with advanced Parkinson's disease, integrating a proprietary liquid pharmaceutical formulation with a portable pump delivery system (YURWAY® Delivery System or Crono Twin ND pump) and digital health solutions.
Is NeuroDerm a public or private company?
NeuroDerm is a private company. It is classified as corporate owned and is currently operating.
When was NeuroDerm founded?
NeuroDerm was founded in 2003. It employs 101 to 250 people.
Where is NeuroDerm based?
NeuroDerm is headquartered in Rehovot, Israel, in the Middle East region.
How does NeuroDerm make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are NeuroDerm's main competitors?
Direct peers on record are AbbVie, Lundbeck, Supernus Pharmaceuticals, Britannia Pharmaceuticals and US WorldMeds. Emerging players are Intec Pharma, Sage Therapeutics and Herantis Pharma. Cerevel Therapeutics is listed as a broad incumbent. Kyowa Kirin is listed as a regional player.
Does NeuroDerm have an API?
No public API is recorded for NeuroDerm.
What industry is NeuroDerm in?
NeuroDerm's product category is Pharmaceutical drug-device combination therapies. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 334510 and its SIC code is 3845.